Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
PACT-15
Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer
- NCT01150630 ↗
- Completed
- IRCCS San Raffaele
- Focused
We haven't built an HCP commentary report on PACT-15 (PEXG in resectable pancreatic adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PACT-15 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II-III Trial of Peri- or Post-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Pancreatic Cancer
- Interventions
- capecitabine; cisplatin; epirubicin; gemcitabine
- Arms
- adjuvant PEXG · Experimental
- perioperative PEXG · Experimental
- Adjuvant Gemcitabine · Active comparator
- Enrollment
- 98
- Primary outcomes
- Event-free survival at 1 year (phase II)
- Sponsor
- IRCCS San Raffaele
- Start
- May 2010
- Primary completion
- Apr 2017
- Results posted
- No
- Registry record
- NCT01150630 · updated Sep 1, 2017
Publications
linked from the registry- Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, Pinelli D, Mosconi S, Doglioni C, Chiaravalli M, Pircher C, Arcidiacono PG, Torri V, Maggiora P, Ceraulo D, Falconi M, Gianni L. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):413-423. doi: 10.1016/S2468-1253(18)30081-5. Epub 2018 Apr 4. PubMed 29625841